Variable Endokrinoloji / Kemik ve Mineral

Paget's Bone Disease — From Incidental Diagnosis to Treatment and Malignant Transformation Warning

Paget's bone disease arises from the EXCESSIVE ACCELERATION of bone breakdown and formation limited to ONE OR A FEW BONES. In this accelerated cycle, the bone produced is IRREGULAR and WEAK; therefore, although the affected bone is THICKER and LARGER, it is WEAKER.

A SIGNIFICANT PORTION of patients are ASYMPTOMATIC, and the diagnosis is made with HIGH ALKALINE PHOSPHATASE found ALONE in tests requested for ANOTHER REASON or changes seen in imaging done for ANOTHER REASON. THEREFORE, THERE IS AN IMPORTANT PRACTICAL RULE:

WHEN LIVER TESTS ARE NORMAL BUT HIGH ALKALINE PHOSPHATASE IS PRESENT ALONE, BONE-RELATED CAUSES, AND ESPECIALLY THIS DISEASE, SHOULD BE CONSIDERED. THE MOST CRUCIAL WARNING IS RELATED TO MALIGNANT TRANSFORMATION: these patients may rarely develop a DEADLY bone cancer, and the only sign may be a CHANGE IN THE CHARACTER OF PAIN or SUDDEN INCREASE.

If this change is mistaken for THE DISEASE'S OWN PAIN, the diagnosis is delayed. BEFORE TREATMENT, VITAMIN D AND CALCIUM SHOULD BE CORRECTED.

Rapid management

BASIC MECHANISM: bone resorption and formation ACCELERATES EXCESSIVELY in ONE OR A FEW BONES; the bone produced in the accelerated cycle is IRREGULAR and FRAGILE → despite being THICKER and LARGER, the affected bone is WEAKER and EASILY FRACTURED.
IMPORTANT PRACTICAL RULE: when LIVER TESTS ARE NORMAL but ALKALINE PHOSPHATASE IS ELEVATED ALONE, BONE-RELATED causes and especially THIS DISEASE should be considered; a significant portion of patients are ASYMPTOMATIC and the diagnosis is INCIDENTAL.
IN SYMPTOMATIC PATIENTS:
BONE PAIN (does not resolve with rest, persists at NIGHT), INCREASED TEMPERATURE OVER THE AFFECTED BONE, BONE DEFORMITY (curvature in leg, growth in skull), JOINT PAIN (radiating to adjacent joint), HEARING LOSS (in base of skull involvement), NERVE COMPRESSION findings.
THE MOST CRUCIAL WARNING — MALIGNANT TRANSFORMATION: a RARE but DEADLY bone cancer can develop; its only sign may be CHANGE IN PAIN CHARACTER, SUDDEN INCREASE, or A NEW SWELLING → this change should not be dismissed as the disease's own pain.
MANDATORY PRE-TREATMENT PREPARATION:
VITAMIN D and CALCIUM are ASSESSED and CORRECTED; otherwise, SEVERE CALCIUM DEFICIENCY may develop during treatment (related protocol).
TREATMENT INDICATIONS:
PAIN, involvement of HIGH-RISK AREAS such as the SKULL BASE and SPINE, PLANNED SURGERY, PROGRESSION OF DEFORMITY.
MONITORING is done using ALKALINE PHOSPHATASE.
IF SURGERY IS PLANNED: the affected bone is OVERLY VASCULARIZED, INCREASING THE RISK OF BLEEDING, and the surgeon should be informed.
In SKULL INVOLVEMENT, HEARING should be evaluated.
ALL DOSES and THRESHOLDS SHOULD BE VERIFIED FROM INSTITUTIONAL PROTOCOL.

Drug	Adult	Pediatric	Route	Duration
Evaluation of elevated alkaline phosphatase alone Paget's bone disease is usually diagnosed not because the patient presents with a specific complaint, but incidentally during testing requested for another reason, and therefore recognizing the diagnosis is directly related to the physician's attention. Alkaline phosphatase is an enzyme derived from both the liver and bile ducts as well as from bone. When this value is found to be elevated in routine blood tests, the first consideration is usually a liver or bile duct problem, and the patient is investigated accordingly. However, when liver function tests are normal, the evaluation often stops there, leaving the elevation unexplained. In this scenario, the source of the enzyme is most likely the bone, indicating a condition in which the bone turnover is accelerated. At this point, Paget's disease should be considered; if necessary, the bone-specific form of the enzyme can be measured to confirm the source. Diagnosis is supported by plain radiographs and, if needed, imaging that evaluates the whole skeleton; this screening shows which bones are involved and whether high-risk areas are affected, thus guiding the treatment decision.	When LIVER TESTS are NORMAL and elevated ALKALINE PHOSPHATASE is detected alone, BONE-RELATED causes should be considered, and this disease should be considered. If necessary, the source can be confirmed with BONE-SPECIFIC measurement. Diagnosis is supported by IMAGING; a WHOLE SKELETON scan can be performed to determine the affected bones. Method selection SHOULD BE VERIFIED FROM INSTITUTIONAL PROTOCOL	This disease does not occur in children; elevated alkaline phosphatase in children may be due to growth and is evaluated differently	Laboratory and imaging	At the time of diagnosis
VITAL WARNING — change in the character of pain The most feared complication of Paget's disease is the development of a malignant tumor in the affected bone. This complication is rare; it occurs in only a very small portion of patients. However, when it develops, its course is rapid and the outcome severe, so early recognition is crucial. The problem is that the early sign of this tumor looks the same as the symptom of the disease itself: pain. Paget's disease already causes bone pain, and the patient may have been living with this pain for years; therefore, an increase or change in pain is often thought to be a flare-up of the disease and is relieved with painkillers. However, the distinguishing feature is not the presence of pain, but the change in its character. A marked increase in pain that has been at a certain level for years within a short period, a change in its nature, waking the patient at night, and decreased response to painkillers are all warning signs. This may be accompanied by a new swelling or a palpable mass on the bone. These changes should be evaluated with imaging, and the patient should be clearly warned.	In these patients, a RARE but FATAL BONE CANCER can develop. THE ONLY SYMPTOM CAN BE A CHANGE IN THE CHARACTER OF PAIN, SUDDEN INCREASE, WAKING FROM SLEEP AT NIGHT, or A NEW SWELLING. This change SHOULD NOT BE DISMISSED AS THE PAIN FROM THE DISEASE ITSELF; it should be evaluated with IMAGING. This warning SHOULD BE EXPLICITLY GIVEN TO THE PATIENT	Not applied	—	Throughout follow-up
Correction of vitamin D and calcium before treatment Correcting vitamin D and calcium status before starting treatment that halts bone resorption in Paget's disease is even more important due to a reason specific to this disease. In this disease, the bone cycle is already excessively accelerated; bone is being both rapidly resorbed and rapidly formed. When treatment strongly suppresses the resorption phase, the ongoing rapid formation phase draws a large amount of calcium from the blood. In a healthy balance, this draw is compensated by absorption from the intestines and release from the bone; however, if there is vitamin D deficiency, absorption is inadequate, and the same drug has also blocked release from bone. The result is a rapid drop in blood calcium. This risk is particularly significant in patients whose disease affects many bones and who have very high enzyme levels, because in these patients the bone cycle is even faster, and the calcium draw caused by treatment is greater. Therefore, assessment should be made before treatment, deficiencies corrected, and adequate intake maintained throughout treatment.	Before starting treatment, VITAMIN D and CALCIUM STATUS SHOULD BE EVALUATED and DEFICIENCY CORRECTED; since the treatment that halts bone resorption abruptly slows the accelerated cycle, SEVERE HYPOCALCEMIA can develop. This risk is HIGHER in patients with WIDESPREAD INVOLVEMENT. Adequate CALCIUM and VITAMIN D intake should be maintained throughout the treatment.	Not applied	Oral	Before and during treatment
Determination of treatment indications In Paget's disease, the treatment decision is based not on the presence of the disease but on the problem it has caused or is expected to cause. The clearest indication is pain; bone pain due to the disease significantly improves with treatment, and this improvement directly increases the patient's quality of life. The second indication is the risk the affected area carries. Skull base involvement can lead to hearing loss and other neurological signs due to thickening of the bone, which narrows the channels through which nerves pass. Spine involvement carries a risk of pressure on the spinal cord and nerve roots. Involvement of weight-bearing long bones can lead to deformity and fracture. When involvement is present in these areas, treatment may be considered even if the patient is asymptomatic. The third indication is planned surgery; excessive vascularization in the affected bone increases bleeding during surgery, so slowing down the cycle with preoperative treatment may be beneficial. On the other hand, in patients with limited involvement, no symptoms, and no risk area involvement, the benefit of treatment is debatable, and the decision should be individualized.	TREATMENT INDICATIONS: Involvement of RISK AREAS such as PAIN, SKULL BASE, and SPINE, PLANNED SURGERY IN THE AFFECTED AREA, PROGRESSION OF DEFORMITY, and NERVE COMPRESSION. In patients who are ASYMPTOMATIC and do not have RISK AREA INVOLVEMENT, the treatment decision is individualized. The choice of medication, dose, and treatment criteria should be VERIFIED FROM THE INSTITUTIONAL PROTOCOL	Not applied	—	At the decision stage
Reporting the risk of bleeding before surgery In Paget's disease, excessive bleeding from the affected bone during surgical intervention, if not known beforehand, is a problem that catches the surgical team unprepared. The cause of this bleeding lies in the nature of the disease itself: the acceleration of the bone cycle significantly increases blood flow to that area, and a dense network of blood vessels develops in the affected bone. This increase is so pronounced that in some patients, the skin over the bone feels warmer to the touch. During surgery, cutting this rich vascular network leads to much more bleeding than expected in a normal bone. This becomes particularly important in large orthopedic interventions, such as hip replacement. Therefore, when surgery is planned on an affected bone, the presence of the disease must be reported to the surgical team; the team can then prepare accordingly. Additionally, slowing the bone cycle with treatment before the intervention can reduce vascularization and limit bleeding, and this option should be considered.	IF SURGERY IS PLANNED IN THE AFFECTED BONE, THE SURGICAL TEAM SHOULD BE INFORMED THAT THIS BONE IS EXCESSIVELY VASCULARIZED AND HAS AN INCREASED RISK OF BLEEDING. Slowing the cycle with preoperative treatment can be considered; the decision and timing should be VERIFIED FROM THE INSTITUTIONAL PROTOCOL	Not applied	—	Preoperative
Evaluation of hearing in skull involvement Involvement of the cranial bones leads to one of the outcomes of Paget's disease that most affects quality of life. Nerves and vessels at the base of the skull pass through narrow channels in the bone; thickening of the bone in this area narrows these channels and compresses the structures passing through them. The most frequently affected function is hearing. The mechanism of hearing loss is not singular; it involves both the structures transmitting sound being affected and damage to the sensory structures in the inner ear and the auditory nerve. An important feature of this loss is its slow progression; the patient may not notice the loss because they adapt to the decreasing hearing or may attribute it to natural age-related changes. Therefore, in patients with skull involvement, hearing should be evaluated even if the patient does not complain. Other consequences of skull involvement include headache, dizziness, tinnitus, and findings related to the involvement of other cranial nerves. Softening and collapse of the skull base is a condition seen in advanced cases and can lead to more serious findings.	In patients with BASE OF SKULL involvement, HEARING should be evaluated; thickening of the bone and involvement of inner ear structures can lead to HEARING LOSS. In addition, HEADACHE, DIZZINESS, TINNITUS, and OTHER NERVE FINDINGS should be questioned. The scope of the evaluation should be CONFIRMED BY INSTITUTIONAL PROTOCOL	Not applied	—	At diagnosis and follow-up
Planning of treatment response and long-term follow-up Monitoring Paget's disease is relatively easy because it can be based on a simple marker reflecting disease activity. Alkaline phosphatase level is directly related to the rate of the bone cycle; it rises when the cycle accelerates and falls when slowed with treatment. Therefore, the response to therapy can be monitored with this value, and approaching normal levels indicates that the treatment is effective. A rise in the value during follow-up suggests reactivation of the disease and may prompt repeated treatment. However, there is a limitation to this marker: in limited disease affecting only a single bone, the enzyme level may remain within normal limits; in these patients, monitoring should be based on clinical findings and imaging. Follow-up should not rely solely on the laboratory; changes in the patient's pain, progression of deformity, and emergence of new nerve findings should be questioned. Changes in the character of pain are of particular importance and should always be evaluated in terms of malignant transformation.	Treatment response is monitored with ALKALINE PHOSPHATASE; a decrease in the value indicates that disease activity has decreased. A RISE again during follow-up suggests that the disease has become active. Additionally, CHANGES IN PAIN, PROGRESSION OF DEFORMITY, and NEW NERVE FINDINGS should be investigated. Follow-up intervals MUST BE VERIFIED FROM THE INSTITUTIONAL PROTOCOL	Not applied	Laboratory	The reason why long-term

Alternative

Bone metastases, widespread bone involvement, and high alkaline phosphatase can be confused.
Multiple myeloma is considered in the differential diagnosis with bone pain and bone changes.
Osteomalacia may be similar with bone pain and high alkaline phosphatase (relevant protocol).
Primary hyperparathyroidism can cause bone changes and elevated alkaline phosphatase (relevant protocol).
Liver and biliary tract diseases are the most common causes of elevated alkaline phosphatase.
Malignant transformation in bone should be considered when the character of pain changes.
Osteoarthritis is considered in the differential diagnosis of adjacent joint pain.
Fibrous dysplasia can cause similar bone imaging changes.

Red flags

A CHANGE IN THE CHARACTER OF PAIN, SUDDEN INCREASE, WAKING FROM NIGHTLY SLEEP, or ASSOCIATION WITH A NEW SWELLING being mistaken for THE DISEASE'S OWN PAIN → A RARE but FATAL BONE CANCER can develop, and this may be its only symptom.
When LIVER TESTS are found NORMAL, leaving HIGH ALKALINE PHOSPHATASE unexplained → the source of the enzyme is most likely BONE.
Not correcting VITAMIN D and CALCIUM before treatment → because the therapy slows down the accelerated cycle suddenly, FAST FORMATION of new bone draws a large amount of calcium from the blood and SEVERE HYPOCALCEMIA develops; the risk is HIGHER IN WIDESPREAD INVOLVEMENT.
Not evaluating HEARING in cranial base involvement → since loss develops SLOWLY, the patient ADJUSTS and DOES NOT NOTICE or attributes it to AGE.
Not informing the SURGICAL TEAM about the disease when planning surgery in the AFFECTED BONE → since the bone is OVERLY VASCULARIZED, bleeding is MUCH GREATER than expected and the team is caught UNPREPARED.
Not questioning neurological findings in SPINAL involvement → there is a risk of COMPRESSION on the spinal cord and nerve roots.
Assuming the affected bone is STRONGER because it is THICKER → the produced bone is IRREGULAR and WEAK, BIGGER but WEAK and EASILY FRACTURED.
Excluding the disease or discontinuing follow-up because ALKALINE PHOSPHATASE is normal in LIMITED disease → in single bone involvement, the enzyme may remain within NORMAL RANGES; follow-up should be based on CLINICAL and IMAGING evaluation.
Automatically starting treatment in asymptomatic patients with NO HIGH-RISK AREA INVOLVEMENT → the benefit in this group is DEBATABLE and the decision should be INDIVIDUALIZED.
Not giving the patient warning about MALIGNANT TRANSFORMATION → they do not know to report changes in pain.
Attributing all pain in adjacent joints to Paget's disease → concomitant OSTEOARTHRITIS should also be evaluated.

Disposition and follow-up

Green zone: Asymptomatic patient with limited involvement and no high-risk area involvement: outpatient follow-up, alkaline phosphatase monitoring, and warning about malignant transformation; treatment decisions are individualized.
Yellow zone: Painful disease, cranial base or spinal involvement, progressive deformity, hearing loss, planned surgery: accelerated evaluation and endocrinology referral; correct vitamin D and calcium before treatment.
Red zone: Change in the character of pain or new swelling: urgent imaging for malignant transformation. Spine involvement with progressive neurological findings: emergency evaluation for compression. Post-treatment muscle spasms and seizures: emergency evaluation for severe hypocalcemia (relevant protocol).

Key clinical points

READ FIRST — thicker bone is not stronger

BASIC MECHANISM: bone DESTRUCTION and FORMATION ACCELERATE EXCESSIVELY in ONE OR A FEW BONES | Bone produced in this accelerated cycle is IRREGULAR and WEAK → the affected bone is THICKER and LARGER but WEAKER and EASILY FRACTURED | This point is counterintuitive: THICKENED BONE SHOULD NOT BE ASSUMED STRONGER | DIAGNOSIS IS MOSTLY INCIDENTAL: a significant portion of patients are ASYMPTOMATIC and the diagnosis is made via HIGH ALKALINE PHOSPHATASE detected in a test requested for ANOTHER REASON or on an X-RAY taken for ANOTHER REASON | PRACTICAL RULE — MECHANISTICALLY: alkaline phosphatase comes from BOTH THE LIVER AND BILE DUCTS AND BONE | When high in routine testing, the first considered usually is a LIVER or BILE DUCT problem | HOWEVER, if liver function tests are NORMAL, assessment OFTEN STOPS here and the elevation is LEFT UNEXPLAINED | YET in this scenario the source of the enzyme is MOST LIKELY BONE → THIS DISEASE SHOULD BE CONSIDERED; if necessary, the source is confirmed with BONE-SPECIFIC measurement | IN SYMPTOMATIC PATIENTS: BONE PAIN (does not subside with rest, also occurs at NIGHT) | increased HEAT over the bone | DEFORMITY | pain in nearby JOINT | HEARING LOSS | NERVE COMPRESSION

In Paget's disease, bone destruction and formation accelerate excessively, limited to one or a few bones; the bone produced is irregular and weak, therefore the affected bone is thicker but weaker and easily fractured. Diagnosis is mostly incidental. Alkaline phosphatase originates from both the liver and bone; when found high in routine tests, the first consideration is usually a liver problem, but if liver tests are normal, assessment often stops and the elevation is left unexplained. Yet in this context, the source is most likely bone and this disease should come to mind. In symptomatic cases, there is bone pain that does not improve with rest, increased heat over the bone, deformity, hearing loss, and nerve compression.

VITAL — if the pain changes, do not ignore it

THE MOST FEARED COMPLICATION: the development of a MALIGNANT TUMOR in the affected bone | RARE (in a VERY SMALL PORTION of patients) but ONCE DEVELOPED, its course is FAST and outcome is SEVERE → EARLY DETECTION IS CRUCIAL | PROBLEM: the EARLY SIGN of this tumor LOOKS THE SAME AS THE SIGN OF THE DISEASE ITSELF — PAIN | Paget's disease ALREADY CAUSES BONE PAIN, and the patient may have been living with this pain for YEARS → an increase or change in the pain is MISTAKEN FOR A FLARE-UP OF THE DISEASE and is RELIEVED WITH PAINKILLERS | WHAT DISTINGUISHES IT IS NOT THE PRESENCE OF PAIN, BUT A CHANGE IN ITS CHARACTER | WARNING SIGNS: a SUDDEN AND NOTICEABLE INCREASE in pain that has been STABLE for years | CHANGE IN NATURE | WAKING THE PATIENT AT NIGHT | LESS RESPONSIVENESS TO PAINKILLERS | This may be accompanied by a NEW SWELLING or a PALPABLE MASS on the bone | RULE: these changes are assessed THROUGH IMAGING and the PATIENT IS CLEARLY WARNED ABOUT THIS

The most feared complication is the development of a malignant tumor in the affected bone. It is rare, but once it develops, its course is fast and the outcome is severe. The problem is that the early sign of this tumor resembles the disease's own symptom: pain. Since Paget's disease already causes bone pain and the patient may have been living with this pain for years, an increase in pain is mistaken for a flare-up of the disease and is managed with painkillers. What is distinctive is not the presence of pain, but a change in its character: a noticeable increase over a short period, change in quality, waking at night, and less responsiveness to painkillers are warning signs. This may be accompanied by a new swelling. These changes should be evaluated through imaging, and the patient should be clearly informed about this warning.

Correct vitamin D and calcium before treatment

IT IS EVEN MORE IMPORTANT FOR THIS DISEASE DUE TO A SPECIFIC REASON | MECHANISM: in this disease, the bone cycle is ALREADY ACCELERATED — the bone is BOTH BEING DESTROYED RAPIDLY AND FORMED RAPIDLY | When treatment strongly suppresses the DESTRUCTION PHASE, the ONGOING RAPID FORMATION PHASE PULLS A LARGE AMOUNT OF CALCIUM FROM THE BLOOD | In a healthy balance, this pull is compensated through ABSORPTION FROM THE INTESTINE and RELEASE FROM THE BONE | HOWEVER, IF THERE IS A VITAMIN D DEFICIENCY, ABSORPTION IS INSUFFICIENT and THE SAME DRUG HAS ALSO BLOCKED RELEASE FROM THE BONE → BLOOD CALCIUM DROPS RAPIDLY | THE RISK IS PARTICULARLY NOTICEABLE in patients where the disease AFFECTS MANY BONES and ENZYME LEVELS ARE VERY HIGH because in these patients the CYCLE IS EVEN FASTER and THE CALCIUM PULL CAUSED BY THE TREATMENT IS LARGER | RULE: evaluate BEFORE treatment, CORRECT DEFICIENCY, and MAINTAIN ADEQUATE INTAKE THROUGHOUT TREATMENT | Doses SHOULD BE VERIFIED FROM THE INSTITUTIONAL PROTOCOL

This preparatory step is also important in Paget’s disease. In this disease, the bone cycle is already extremely accelerated; the bone is both rapidly destroyed and formed. When the treatment suppresses the destruction phase, the ongoing rapid formation phase pulls a large amount of calcium from the blood. In a healthy balance, this pull is met by absorption from the intestine and release from the bone; however, if there is a vitamin D deficiency, absorption is inadequate and the same drug has blocked release from the bone as well, resulting in a rapid drop in blood calcium. The risk is particularly obvious in patients where many bones are involved and enzyme levels are very high because the cycle is faster. Therefore, an evaluation should be done before treatment and deficiencies should be corrected.

Treatment decision and surgical bleeding warning

The decision for treatment is based not on the presence of the disease, but on the problem it has caused or is expected to cause | (1) PAIN — THE MOST CLEAR INDICATION: bone pain due to the disease CLEARLY IMPROVES with treatment | (2) RISK OF THE AFFECTED AREA: BASE OF THE SKULL involvement — due to the bone THICKENING AND NARROWING THE CHANNELS THROUGH WHICH NERVES PASS, HEARING LOSS and other nerve symptoms | SPINAL involvement — risk of PRESSURE on the SPINAL CORD and NERVE ROOTS | LOAD-BEARING LONG BONES — DEFORMATION and FRACTURE | If these areas are involved, treatment is considered even if the patient is ASYMPTOMATIC | (3) PLANNED SURGERY | In patients who are ASYMPTOMATIC and do not have INVOLVEMENT OF RISKY AREAS, the benefit of treatment is DEBATABLE → the decision is INDIVIDUALIZED | BLEEDING IN SURGERY — MECHANISM: excessive acceleration of the bone cycle requires a SIGNIFICANT INCREASE in BLOOD FLOW in that area, and an INTENSE VASCULAR NETWORK develops in the affected bone | This increase is SO PROMINENT THAT in some patients, the SKIN OVER THE BONE FEELS WARMER TO TOUCH | During surgery, CUTTING THIS RICH VASCULAR NETWORK leads to MUCH MORE BLEEDING than expected in a NORMAL BONE in the same area (especially in major orthopedic procedures like HIP REPLACEMENT) | RULE: the presence of the disease MUST BE REPORTED TO THE SURGICAL TEAM ; slowing the cycle with treatment before the procedure can LIMIT bleeding by REDUCING VASCULARIZATION

The treatment decision is based not on the presence of the disease but on the problem it causes. The clearest indication is pain. The second indication is the risk of the affected area: base of the skull involvement causes hearing loss by narrowing nerve channels, spinal involvement carries a risk of pressure, load-bearing bones can deform and fracture; treatment is considered for these areas even if the patient is asymptomatic. In patients who are asymptomatic and without involvement of risky areas, the benefit is debatable. The risk of bleeding in surgery arises from the increased blood flow due to accelerated bone cycle; in some patients, the skin over the bone feels warmer. Cutting this rich vascular network causes more bleeding than expected, and the disease must be reported to the surgical team.

Hearing, monitoring, and enzyme boundary

SKULL INVOLVEMENT and HEARING: nerves and blood vessels at the base of the skull pass through NARROW CHANNELS in the bone → thickening of the bone NARROWS these channels and COMPRESSES the structures passing through them | THE MOST FREQUENTLY AFFECTED FUNCTION IS HEARING, and ITS MECHANISM IS NOT SINGLE: both the affected structures that TRANSMIT SOUND and the DAMAGE TO THE SENSORY STRUCTURES in the INNER EAR and the AUDITORY NERVE play a role | IMPORTANT FEATURE: the loss DEVELOPS SLOWLY → the patient may NOT NOTICE the loss or MISTAKE it for A NATURAL AGE-RELATED CHANGE because they ADAPT TO DECREASING HEARING → hearing should be evaluated in individuals with skull involvement EVEN IF THE PATIENT DOES NOT COMPLAIN | Other outcomes: HEADACHE | DIZZINESS | RINGING IN THE EAR | other CRANIAL NERVE findings | IN ADVANCED CASES, the base of the skull SOFTENS AND COLLAPSES | MONITORING: ALKALINE PHOSPHATASE is DIRECTLY RELATED TO THE SPEED OF THE BONE CYCLE → it RISES when the cycle accelerates, and FALLS when slowed with treatment; a RISE AGAIN during monitoring suggests the disease has REACTIVATED | HOWEVER, THIS INDICATOR HAS A LIMITATION: in LIMITED disease involving only a SINGLE BONE, the enzyme may remain WITHIN NORMAL LIMITS → in these patients, monitoring relies on CLINICAL FINDINGS and IMAGING | Monitoring DOES NOT RELY SOLELY ON LABORATORY RESULTS: CHANGES IN PAIN, PROGRESSION OF SHAPE DEFORMITY, and NEW NERVE FINDINGS are questioned | ANY CHANGE IN THE CHARACTER OF PAIN is ALWAYS evaluated for MALIGNANT TRANSFORMATION

Nerves and blood vessels at the base of the skull pass through narrow channels within the bone; thickening of the bone narrows these channels. The most frequently affected function is hearing, and its mechanism is not single. Since the loss develops gradually, the patient adapts and may not notice it or may consider it age-related; therefore, hearing should be evaluated in individuals with skull involvement even if the patient does not complain. In monitoring, alkaline phosphatase is directly related to the speed of the bone cycle and decreases with treatment; a renewed rise suggests the disease is reactivated. However, in limited disease involving only a single bone, the enzyme may remain normal and monitoring should rely on clinical findings and imaging. Any change in the character of pain must always be evaluated in terms of malignant transformation.

Featured external sources

Endocrine Society Paget disease guideline.ALP, imaging, treatment, and follow-up recommendations.
2019 Paget disease clinical guideline.Targeted radiography, bone scintigraphy, and zoledronate recommendations.
Endocrine Society clinical practice guidelines.Guideline methodology and up-to-date endocrine reference index.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

Paget's bone disease occurs with an accelerated bone destruction and formation restricted to one or a few bones; because the bone produced in this accelerated cycle is irregular and fragile, the affected bone is thicker yet weaker. A significant portion of patients are asymptomatic, and the diagnosis is made through a test requested for another reason showing an isolated high alkaline phosphatase or an imaging film taken for another reason.

For this reason, there is an important practical rule: when liver tests are normal, isolated high alkaline phosphatase should suggest bone-related causes, especially this disease. The most critical warning concerns malignant transformation; a rare but fatal bone cancer can develop, and the only sign may be a change in the character of pain, which should not be dismissed as the disease's own pain.

Before treatment, vitamin D and calcium should be corrected because a sudden slowing of the accelerated cycle can lead to severe hypocalcemia. In skull involvement, hearing should be evaluated, and if surgery is planned, the risk of bleeding should be reported.

Differential diagnosis and assessment

Key considerations

Bone metastases can be confused with widespread involvement and high alkaline phosphatase.
Multiple myeloma is considered in the differential diagnosis with bone pain and bone changes.
Osteomalacia may be similar with bone pain and high alkaline phosphatase (relevant protocol).
Primary hyperparathyroidism can cause bone changes (relevant protocol).
Liver and biliary tract diseases are the most common causes of elevated alkaline phosphatase.
Malignant transformation in bone should be considered when the character of pain changes.
Osteoarthritis is considered in the differential diagnosis of adjacent joint pain and may coexist.
Fibrous dysplasia can cause similar imaging changes.

Clinical decision reasoning

Why it matters

The key points determining the clinical outcome in the management of Paget's bone disease arise from the silent course of the disease and the overlap of its symptoms with complications. The first point is how the diagnosis comes to mind; since alkaline phosphatase originates from both the liver and bone, when liver tests are found to be normal, the assessment often stops and a bone-derived disease is overlooked.

The second and most critical point is malignant transformation; the early sign of this tumor is the same as the disease's own symptom, so an increase in pain is mistaken for a flare-up, whereas the distinguishing factor is not the presence of pain but the change in its character. The third point is pre-treatment preparation; since the cycle in this disease is already fast, suppression of destruction causes a large amount of calcium to be drawn from the blood by the ongoing rapid formation, and if there is vitamin D deficiency, calcium drops rapidly.

The fourth point is surgical bleeding; the dense vascular network required by the accelerated cycle leads to unexpected bleeding during the procedure and this information should be provided to the team in advance. The final point is the limitation of the monitoring marker; in localized disease, the enzyme can remain normal, so monitoring based solely on laboratory results is misleading.

Safety and monitoring

Complications and safety

Critical complications

Malignant transformation is rare but progresses rapidly and has a severe outcome.
Fractures occur in the affected bone because, although the bone is thicker, it is fragile.
Hearing loss and other nerve findings are seen due to skull base involvement.
In spinal involvement, pressure on the spinal cord and nerve roots may develop.
Deformity and associated gait problems, along with adjacent joint disease, arise.
Excessive bleeding during surgery causes problems if the disease is not reported.
Severe calcium deficiency due to treatment occurs if preparation is not made.
Increased heart load may be observed in very widespread involvement.

Special patient populations

Special considerations

In patients with widespread involvement and very high enzyme levels, the risk of treatment-related calcium deficiency is higher.
Hearing should be regularly evaluated in those with skull base involvement.
Neurological findings should be monitored in those with spinal involvement.
The risk of bleeding should be reported to the team in patients planned for surgery in the affected bone.
Correction before treatment is obligatory in those with vitamin D deficiency.
In individuals with bone involvement carrying weight, the risk of fracture and deformity should be monitored.
The disease may be more frequent in those with a family history.
This disease does not occur in children, and similar findings in a child should be evaluated differently.

Follow-up and reassessment

Follow-up plan

In Paget's bone disease, follow-up should cover both the activity of the disease and its complications. The alkaline phosphatase level should be evaluated at intervals specified by the institutional protocol; the response to treatment should be monitored with this value, and a renewed rise should suggest disease activation.

However, in patients with limited involvement, this enzyme may remain within normal limits, so follow-up should not rely solely on laboratory tests; clinical findings and imaging should be used when necessary. At each visit, the nature of pain should also be asked; an increase in pain, change in its character, awakening from sleep at night, or the presence of a new swelling should be evaluated for malignant transformation and these changes should not be dismissed as the disease's own pain.

This warning should be given to the patient at the time of diagnosis and repeated during follow-up. In patients with skull base involvement, hearing should be assessed regularly even if the patient does not complain.

In those with spinal involvement, new neurological findings should be asked. It should be monitored whether the deformity is progressing and whether gait is affected.

Vitamin D and calcium intake should be maintained, and calcium levels should be evaluated in the post-treatment period. When surgery is planned on an affected bone, the presence of the disease should be communicated to the surgical team.